Objective： To observe the efficacy and safety of Jingui Shengqi Pill （金匮肾气丸, JSP） in treating partial androgen deficiency in aging males （PADAM）, and to explore the new approach in improving the quality of l...Objective： To observe the efficacy and safety of Jingui Shengqi Pill （金匮肾气丸, JSP） in treating partial androgen deficiency in aging males （PADAM）, and to explore the new approach in improving the quality of life in PADAM patients. Methods： Forty patients with PADAM were treated with JSP, the efficacy was evaluated with international index of erectile function （IIEF） scoring, PADAM questionnaire scoring, hormone, prostatic specific antigen （PSA）, etc., and the data before treatment were compared with those after treatment in the same group. Results： After 3 months of treatment, PADAM scoring and IIEF scoring were all significantly improved. Symptoms regarding physical ability, vasomotion, and psychical and mental condition all got improved more markedly than symptoms regarding sexual hypofunction. The serum level of testosterone was 3.85±0.36 before treatment and 5.02±0.83 after treatmnet （P〈0.05）; luteinizing hormone of 7.33±2.14 and 4.84±1.43 （P〈0.01）, follicule-stimulating hormone of 10.22±4.48 and 6.47±3.28 （P〈0.01）, respectively. The level of PSA failed to change significantly （1.94±0.55 and 2.06±0.47, P〉0.05）. Conclusion： JSP is effective and safe in treating PADAM, the mechanism of it is different from supplementing extrinsic androgen. It may have produced the effect by means of favorably regulating the condition of sex hormone to improve the balance of pituitary-sex gland axis, so it has more extensive clinical application.展开更多
Background Partial androgen deficiency syndrome in the aging male is associated with signs of aging such as a development of abdominal obesity,sexual dysfunction,increase body fat,weight gain and the development of ca...Background Partial androgen deficiency syndrome in the aging male is associated with signs of aging such as a development of abdominal obesity,sexual dysfunction,increase body fat,weight gain and the development of cardiac disease.Objective We assessed the outcome of a commercially available physician supervised nutrition and exercise program with concomitant testosterone replacement therapy in middle age obese men with partial androgen deficiency in order to reduce cardiac risks factors.Methods Fifty-six self referred men without diabetes mellitus,hypertension,or cardiovascular disease(ages 52.3±7.8 years)were randomly selected from a large cohort.Baseline weight,body fat composition,fasting glucose,hemoglobin A1c and fasting lipid levels,as well as free and total testosterone levels were assessed.All patients were assessed and followed 6–18 months after initiation of the program.The program consisted of a low glycemic load balanced nutrition diet,a recommended structured daily exercise program of 30–60 minutes,as well as once to twice weekly intramuscular testosterone injections(113.0±27.8 mg).Results At follow up,weight was reduced from 233.9±30.0 pounds(lbs)to 221.3±25.1 lbs(P<0.001),BMI was reduced from 33.2±3.3 kg/m2 to 31.3±2.8 kg/m^(2)(P<0.0001).Total body fat was 27.1%±5.2%vs.34.3%±5.7%at baseline(P<0.0001).Fasting glucose was reduced from 95.3±14.4 mg/dL to 87.5±12.6 mg/dL(P<0.0001).Total cholesterol was reduced from 195.4±33.0 mg/dL to 172.7±35.0 mg/dL(P<0.005).No clinically significant adverse events were recorded.Conclusions Testosterone replacement therapy in middle aged obese men with partial androgen deficiency appeared safe and might have promoted the effects of a weight reduction diet and daily exercise program as long as an adequate physician supervision and follow up was granted.The combination therapy significantly reduced coronary risk factors such as glucose intolerance and hyperlipidemia.展开更多
AIM:To investigate the effects of exogenous testosterone treatment on the choroidal parameters in patients with androgen deficiency.METHODS:Right eyes of 24 patients with androgen deficiency and 31 healthy volunteers ...AIM:To investigate the effects of exogenous testosterone treatment on the choroidal parameters in patients with androgen deficiency.METHODS:Right eyes of 24 patients with androgen deficiency and 31 healthy volunteers were included in the study.The eyes were scanned for subfoveal choroidal thickness(SFCT),choroidal vascularity index(CVI),choroidstromal area(C-SA),choroid-luminal area(C-LA),choroidstromal to luminal area ratio(CSLR),and the choroidal parameters within central 1500μm of the macula(CVI1500,C-LA1500,C-SA1500,and CSLR1500)by enhanced-depth imaging optical coherence tomography(EDI-OCT)at baseline,6th and 18th weeks of the exogenous testosterone treatment.RESULTS:The mean SFCT values of the androgen deficient groups and healthy controls were 307.7±27.0 and 303.2±37.2μm(P=0.8).However,CVI,C-SA,CSLR,CVI1500,C-LA1500,and CSLR1500 were significantly different between the groups(all P<0.01).At the 6th week visit after exogenous testosterone treatment,SFCT,CVI,C-LA,and C-SA were significantly decreased,and these parameters returned to baseline levels at the 18th-week visit(all P>0.05).However,CVI1500 and LA1500 significantly increased at the end of the follow-up period(P<0.001).CONCLUSION:CVI is lower in androgen-deficient patients than in healthy subjects.The alterations in the choroid during the testosterone peak are transient in the treatment of patients with androgen deficiency.However,the increase in CVI within the central 1500μm of the macula persists even after 4mo.展开更多
本文主要研究肾阳虚(kidney yang deficiency)小鼠血清睾酮及性腺雄激素受体基因的表达,旨在揭示淫羊藿苷(icariin)对肾阳虚症状的影响.雄性小鼠随机分为6组,除正常组注射生理盐水外,其余组注射氢化可的松15 d;再分别给大、中、小剂量...本文主要研究肾阳虚(kidney yang deficiency)小鼠血清睾酮及性腺雄激素受体基因的表达,旨在揭示淫羊藿苷(icariin)对肾阳虚症状的影响.雄性小鼠随机分为6组,除正常组注射生理盐水外,其余组注射氢化可的松15 d;再分别给大、中、小剂量组淫羊藿苷,阳性组甲基睾酮,正常组和模型对照组蒸馏水,灌胃15 d.放射免疫法测血清中睾酮含量;RT-PCR和免疫组织化学方法检测雄激素受体基因在性腺组织中mRNA和蛋白质的表达情况.对照组小鼠平均体重最轻,与正常组比较差异显著(P<0.05).对照组小鼠血清睾酮的含量显著低于正常组(P<0.05);大、中剂量给药组,阳性组睾酮与正常组相比差异不显著(P>0.05);性腺组织中,对照组雄激素受体和mRNA比正常组表达量低,差异显著(P<0.05);中、小剂量给药组,阳性组雄激素受体和mRNA与正常组相比差异不显著(P>0.05).结果表明,肾阳虚小鼠血清睾酮含量,性腺雄激素受体mRNA和蛋白质的表达与正常组相比均有所下降,淫羊藿苷能够抑制其下降,缓解肾阳虚症状.展开更多
文摘Objective： To observe the efficacy and safety of Jingui Shengqi Pill （金匮肾气丸, JSP） in treating partial androgen deficiency in aging males （PADAM）, and to explore the new approach in improving the quality of life in PADAM patients. Methods： Forty patients with PADAM were treated with JSP, the efficacy was evaluated with international index of erectile function （IIEF） scoring, PADAM questionnaire scoring, hormone, prostatic specific antigen （PSA）, etc., and the data before treatment were compared with those after treatment in the same group. Results： After 3 months of treatment, PADAM scoring and IIEF scoring were all significantly improved. Symptoms regarding physical ability, vasomotion, and psychical and mental condition all got improved more markedly than symptoms regarding sexual hypofunction. The serum level of testosterone was 3.85±0.36 before treatment and 5.02±0.83 after treatmnet （P〈0.05）; luteinizing hormone of 7.33±2.14 and 4.84±1.43 （P〈0.01）, follicule-stimulating hormone of 10.22±4.48 and 6.47±3.28 （P〈0.01）, respectively. The level of PSA failed to change significantly （1.94±0.55 and 2.06±0.47, P〉0.05）. Conclusion： JSP is effective and safe in treating PADAM, the mechanism of it is different from supplementing extrinsic androgen. It may have produced the effect by means of favorably regulating the condition of sex hormone to improve the balance of pituitary-sex gland axis, so it has more extensive clinical application.
基金supported by the Cenegenics Education and Research Foundation,a non-profit entity.
文摘Background Partial androgen deficiency syndrome in the aging male is associated with signs of aging such as a development of abdominal obesity,sexual dysfunction,increase body fat,weight gain and the development of cardiac disease.Objective We assessed the outcome of a commercially available physician supervised nutrition and exercise program with concomitant testosterone replacement therapy in middle age obese men with partial androgen deficiency in order to reduce cardiac risks factors.Methods Fifty-six self referred men without diabetes mellitus,hypertension,or cardiovascular disease(ages 52.3±7.8 years)were randomly selected from a large cohort.Baseline weight,body fat composition,fasting glucose,hemoglobin A1c and fasting lipid levels,as well as free and total testosterone levels were assessed.All patients were assessed and followed 6–18 months after initiation of the program.The program consisted of a low glycemic load balanced nutrition diet,a recommended structured daily exercise program of 30–60 minutes,as well as once to twice weekly intramuscular testosterone injections(113.0±27.8 mg).Results At follow up,weight was reduced from 233.9±30.0 pounds(lbs)to 221.3±25.1 lbs(P<0.001),BMI was reduced from 33.2±3.3 kg/m2 to 31.3±2.8 kg/m^(2)(P<0.0001).Total body fat was 27.1%±5.2%vs.34.3%±5.7%at baseline(P<0.0001).Fasting glucose was reduced from 95.3±14.4 mg/dL to 87.5±12.6 mg/dL(P<0.0001).Total cholesterol was reduced from 195.4±33.0 mg/dL to 172.7±35.0 mg/dL(P<0.005).No clinically significant adverse events were recorded.Conclusions Testosterone replacement therapy in middle aged obese men with partial androgen deficiency appeared safe and might have promoted the effects of a weight reduction diet and daily exercise program as long as an adequate physician supervision and follow up was granted.The combination therapy significantly reduced coronary risk factors such as glucose intolerance and hyperlipidemia.
文摘AIM:To investigate the effects of exogenous testosterone treatment on the choroidal parameters in patients with androgen deficiency.METHODS:Right eyes of 24 patients with androgen deficiency and 31 healthy volunteers were included in the study.The eyes were scanned for subfoveal choroidal thickness(SFCT),choroidal vascularity index(CVI),choroidstromal area(C-SA),choroid-luminal area(C-LA),choroidstromal to luminal area ratio(CSLR),and the choroidal parameters within central 1500μm of the macula(CVI1500,C-LA1500,C-SA1500,and CSLR1500)by enhanced-depth imaging optical coherence tomography(EDI-OCT)at baseline,6th and 18th weeks of the exogenous testosterone treatment.RESULTS:The mean SFCT values of the androgen deficient groups and healthy controls were 307.7±27.0 and 303.2±37.2μm(P=0.8).However,CVI,C-SA,CSLR,CVI1500,C-LA1500,and CSLR1500 were significantly different between the groups(all P<0.01).At the 6th week visit after exogenous testosterone treatment,SFCT,CVI,C-LA,and C-SA were significantly decreased,and these parameters returned to baseline levels at the 18th-week visit(all P>0.05).However,CVI1500 and LA1500 significantly increased at the end of the follow-up period(P<0.001).CONCLUSION:CVI is lower in androgen-deficient patients than in healthy subjects.The alterations in the choroid during the testosterone peak are transient in the treatment of patients with androgen deficiency.However,the increase in CVI within the central 1500μm of the macula persists even after 4mo.
基金Supported by National Natural Science Foundation of China (No. 10874108)~~
文摘本文主要研究肾阳虚(kidney yang deficiency)小鼠血清睾酮及性腺雄激素受体基因的表达,旨在揭示淫羊藿苷(icariin)对肾阳虚症状的影响.雄性小鼠随机分为6组,除正常组注射生理盐水外,其余组注射氢化可的松15 d;再分别给大、中、小剂量组淫羊藿苷,阳性组甲基睾酮,正常组和模型对照组蒸馏水,灌胃15 d.放射免疫法测血清中睾酮含量;RT-PCR和免疫组织化学方法检测雄激素受体基因在性腺组织中mRNA和蛋白质的表达情况.对照组小鼠平均体重最轻,与正常组比较差异显著(P<0.05).对照组小鼠血清睾酮的含量显著低于正常组(P<0.05);大、中剂量给药组,阳性组睾酮与正常组相比差异不显著(P>0.05);性腺组织中,对照组雄激素受体和mRNA比正常组表达量低,差异显著(P<0.05);中、小剂量给药组,阳性组雄激素受体和mRNA与正常组相比差异不显著(P>0.05).结果表明,肾阳虚小鼠血清睾酮含量,性腺雄激素受体mRNA和蛋白质的表达与正常组相比均有所下降,淫羊藿苷能够抑制其下降,缓解肾阳虚症状.
